Skip to main content

Table 3 Multivariate Cox-regression survival analysis

From: Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients

A

 

Disease specific survival

Overall survival

  

Regression model without NFE2L2 mRNA expression

Regression model incl. NFE2L2 mRNA expression

Regression model without NFE2L2 mRNA expression

Regression model incl. NFE2L2 mRNA expression

Variable

 

HR (95 % CI)

P

HR (95 % CI)

P

HR (95 % CI)

P

HR (95 % CI)

P

Size

T1 vs. T2/3/4

1.5 (1.2–2.0)

0.003

1.5 (1.2–2.0)

0.002

1.5 (1.2–1.8)

0.001

1.5 (1.2–1.9)

0.001

LN

neg. vs. pos.

1.7 (1.2–2.3)

0.002

1.7 (1.2–2.4)

0.001

1.5 (1.2–2.0)

0.002

1.6 (1.2–2.1)

0.001

Tumour grade

I vs. II vs. III

1.4 (1.1 -1.9)

0.008

1.4 (1.1 -1.8)

0.014

1.3 (1.0 -1.6)

0.026

1.3 (1.0 -1.6)

0.043

MP

pre vs. post

1.3 (0.9–1.7)

0.139

1.2 (0.9–1.7)

0.175

1.7 (1.2–2.2)

<0.001

1.6 (1.2–2.1)

0.001

HER2

neg. vs. pos.

1.6 (1.2–2.2)

0.002

1.7 (1.2–2.2)

0.001

1.5 (1.1–2.0)

0.004

1.5 (1.2–2.0)

0.002

ER

neg. vs. pos.

1.2 (0.8–1.8)

0.432

1.2 (0.8–1.7)

0.466

1.1 (0.8–1.6)

0.449

1.1 (0.8–1.6)

0.496

Histology

 

0.9 (0.7–1.2)

0.422

0.9 (0.7–1.2)

0.462

1.0 (0.8–1.2)

0.641

1.0 (0.8–1.2)

0.695

Chemotherapy

no vs. yes

1.7 (1.1–2.5)

0.014

1.7 (1.1–2.5)

0.015

1.5 (1.0–2.2)

0.027

1.5 (1.0–2.2)

0.030

Radiation therapy

no vs. yes

1.0 (0.7–1.3)

0.955

1.0 (0.7–1.3)

0.850

0.9 (0.7–1.1)

0.298

0.9 (0.7–1.1)

0.232

Endocrine therapy

no vs. yes

0.8 (0.6–1.1)

0.211

0.8 (0.6–1.1)

0.232

0.8 (0.6–1.1)

0.214

0.8 (0.6–1.1)

0.253

NFE2L2 mRNA expression

low vs. high (< or > 65th %ile)

-

-

0.8 (0.6–1.0)

0.041

-

-

0.8 (0.6–1.0)

0.023

B

 

Relapse-free survival

Overall survival

  

Regression model without NFE2L2 mRNA expression

Regression model incl. NFE2L2 mRNA expression

Regression model without NFE2L2 mRNA expression

Regression model incl. NFE2L2 mRNA expression

Variable

 

HR (95 % CI)

P

HR (95 % CI)

P

HR (95 % CI)

P

HR (95 % CI)

P

Size

T1 vs. T2/3/4

1.9 (0.8–4.3)

0.120

2.0 (0.9–4.5)

0.098

1.6 (0.8–3.2)

0.176

1.6 (0.8–3.2)

0.154

LN

neg. vs. pos.

1.4 (0.7–2.9)

0.368

1.3 (0.6–2.7)

0.539

2.2 (1.2–4.3)

0.015

2.1 (1.1–4.1)

0.025

Tumour grade

I vs. II vs. III

1.1 (0.6–2.1)

0.709

1.3 (0.7–2.5)

0.378

0.8 (0.5–1.2)

0.257

0.8 (0.5–1.4)

0.455

MP

pre vs. post

1.0 (0.5–2.1)

0.892

1.1 (0.5–2.2)

0.817

2.0 (1.0–4.0)

0.044

2.0 (1.0–4.0)

0.038

HER2

neg. vs. pos.

1.0 (0.5–2.0)

0.995

1.0 (0.5–2.0)

0.995

1.3 (0.8–2.3)

0.342

1.4 (0.8–2.4)

0.292

ER

neg. vs. pos.

0.5 (0.1–1.7)

0.257

0.4 (0.1–1.5)

0.177

1.0 (0.4–2.8)

0.990

0.9 (0.3–2.5)

0.824

PR

neg. vs. pos.

1.0 (0.4–2.8)

0.992

1.2 (0.4–3.6)

0.726

1.0 (0.4–2.5)

0.982

1.1 (0.5–2.9)

0.782

Histology

 

0.7 (0.4–1.3)

0.270

0.6 (0.3–1.1)

0.107

1.2 (0.7–2.1)

0.533

1.2 (0.6–2.1)

0.659

Chemotherapy

no vs. yes

1.4 (0.7–3.0)

0.366

1.3 (0.6–2.8)

0.495

0.9 (0.5–1.7)

0.831

0.9 (0.5–1.6)

0.684

Radiation therapy

no vs. yes

1.6 (0.8–3.1)

0.202

1.5 (0.7–2.9)

0.277

0.8 (0.5–1.3)

0.374

0.8 (0.4–1.3)

0.308

Endocrine therapy

no vs. yes

1.2 (0.5–3.0)

0.731

1.3 (0.5–3.4)

0.563

0.7 (0.3–1.5)

0.358

0.7 (0.4–1.5)

0.431

NFE2L2 mRNA expression

low vs. high (< or > 65th %ile)

-

-

0.4 (0.2–0.9)

0.031

-

-

0.6 (0.3–1.2)

0.135

 

low vs. high (< or > median)

-

-

0.3 (0.1–0.6)

0.001

-

-

0.5 (0.3–0.8)

0.010

  1. Abbreviations: LN lymph node status, MP menopausal status, HER2 human epidermal growth factor receptor 2 status, ER oestrogen receptor status, PR progesterone receptor status, HR hazard ratio
  2. (A) Disease specific survival and overall survival in 1942 breast cancer patients (METABRIC dataset). (B) Relapse-free survival and overall survival in 176 patients with primary breast cancer
  3. Bold values have a significance level of P < 0.05
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us